CLARITY PHARMACEUTICALS LTD

5.45%

$2.08

Market Cap $668.4M

Healthcare Biotechnology

Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical... Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. It is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. It has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.More

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. WEBINAR: What investors should know about what it takes for ASX-listed companies to get medical developments...

Latest Threads

Tag

Subject

CU6

CU6 - ASX Charts

41 42 43

20/06/25

2.5K

973K

20/06/25

Last post Vivo

2.5K

973K

CU6

Ann: Clarity enters a Commercial Manufacturing Agreement

20/06/25

7.4K

20/06/25

Last post wednesdayschild

7.4K

CU6

CU6 - Media and Industry News

20 21 22

19/06/25

1.2K

558K

19/06/25

Last post Johnnykb

1.2K

558K

CU6

Ann: DISCO topline results

17/06/25

31K

17/06/25

Last post htae39

31K

CU6

Ann: SABRE topline results

15/06/25

15K

15/06/25

Last post ttppxx

15K

CU6

CU6 - General discussion

8 9 10

05/06/25

551

224K

05/06/25

Last post longreach

551

224K

CU6

Ann: Ceasing to be a substantial holder

05/06/25

434

05/06/25

Last post

ASX News

434

CU6

Ann: First patient imaged in Phase III AMPLIFY trial

03/06/25

11K

03/06/25

Last post Coit

11K

See All Discussions

Timeline

Clarity enters a Commercial Manufacturing Agreement
17 Jun 09:36	Share

SABRE topline results
13 Jun 09:58	Share

DISCO topline results
05 Jun 09:49	Share

Ceasing to be a substantial holder
05 Jun 08:22	Share

Notification regarding unquoted securities - CU6
30 May 11:08	Share

First patient imaged in Phase III AMPLIFY trial
29 May 09:34	Share

AMPLIFY trial commences
20 May 09:55	Share

Ceasing to be a substantial holder
15 May 16:24	Share

Becoming a substantial holder
13 May 15:43	Share

Change in substantial holding
02 May 08:26	Share

Quarterly Activities/Appendix 4C Cash Flow Report
30 Apr 15:06	Share

Change in substantial holding
22 Apr 18:51	Share

Ceasing to be a substantial holder
17 Apr 16:33	Share

Clarity signs commercial-scale copper-64 Supply Agreement
17 Apr 09:55	Share

$11.1 million RDTI and refocus on high-priority programs
17 Apr 09:53	Share

Becoming a substantial holder
16 Apr 15:43	Share

First patient treated in the Phase II of the SECuRE trial
15 Apr 09:40	Share

Change of Registered Office and Registry Address
14 Apr 10:01	Share

Becoming a substantial holder
11 Apr 08:21	Share

Notification of cessation of securities - CU6
10 Apr 17:18	Share

Becoming a substantial holder
09 Apr 18:26	Share

Cleansing Notice
05 Mar 13:57	Share

Application for quotation of securities - CU6
05 Mar 13:51	Share

Clarity signs Cu-64 Supply Agreement with UQ
05 Mar 09:57	Share

SECuRE trial update
05 Mar 09:55	Share

Half Yearly Report and Accounts
28 Feb 15:52	Share

Appendix 4D
28 Feb 15:52	Share

Clarity receives US FDA FTD for the treatment of mCRPC
19 Feb 09:31	Share

Response to ASX Cleansing Notice Timing Letter
18 Feb 11:04	Share

Cleansing Notice
11 Feb 14:00	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $2.08		Change -0.120(5.45%)		Mkt cap ! $668.4M

Open	High	Low	Value	Volume
$2.21	$2.24	$2.01	$13.25M	6.372M

Buyers (Bids)

No.	Vol.	Price($)
1	10460	$2.07

Sellers (Offers)

Price($)	Vol.	No.
$2.08	73748	4

View Market Depth

No.	Vol.	Price($)
4	63305	2.060
8	95326	2.050
9	168812	2.040
9	122985	2.030
13	90055	2.020

Price($)	Vol.	No.
2.080	73748	4
2.090	43311	6
2.100	161903	5
2.110	51097	4
2.120	81840	6

Last trade - 16.10pm 20/06/2025 (20 minute delay)

CU6 (ASX) Chart

CLARITY PHARMACEUTICALS LTD

Latest Threads

Thick, High-Grade Gold Intercepts Demonstrate Robustness of Apollo Hill Resource

Timeline

Featured News

Latest Videos

Clarity Pharmaceuticals' (ASX:CU6) theranostic prostate cancer trial progresses to highest dose level

10 Aug 2023 12:13 (AEST)

Latest Articles

Clarity scribes deal on delivery of copper 64 isotopes

Clarity Pharmaceuticals Ltd has seen its share price leap after it announced a deal with Nusano to deliver Cu-64 isotopes

Another win for Clarity at FDA as imaging agent fast-tracked for complex prostate cancer

For those unlucky enough to have received a testicular castration to treat prostate cancer, only for it to come back, Clarity Pharmaceuticals’ (ASX:CU6) news on Wednesday morning could offer crucial moral support.For those patients (who have also already received first-stage less ...

Clarity jumps as FDA awards fast track status for PET scan imaging agent

Clarity Pharmaceuticals (ASX:CU6) has seen the U.S. FDA fast-track its prostate cancer imaging compound for use in PET scans on patients with recurring prostate cancer. The stock jumped 4% in the first hour of trade to $4.23 in what is likely a welcome move for shareholders who have already seen ...

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News